Why Parkinson's and dementia remain the hardest targets
Quick answer
PDSTEM is EHL Bio's pipeline cell drug aimed at Parkinson's disease. Neurodegeneration is hard because dead neurons do not regrow and therapies must cross the blood-brain barrier, so cell approaches focus on calming neuroinflammation and protecting surviving neurons rather than replacing lost ones.
In Parkinson's, dopamine-producing neurons in the substantia nigra die off gradually, and tremor, rigidity and slowness appear only after substantial loss. Standard therapy such as levodopa controls symptoms well but does not halt the underlying degeneration.
Cell research instead tries to change the environment around neurons: dialling down overactive microglia, reducing oxidative stress and adding neurotrophic support. That is why trials measure clinical scales such as UPDRS alongside long follow-up windows.
For Thai families the blunt advice is to expect no cure and to always ask three things: what research stage the product is at, what outcome measure is used, and what follow-up is planned. This disease group attracts the most overstated marketing.
The MSCs used clinically generally do not become neurons; they act through secreted factors that reduce inflammation and protect existing cells.
Never stop on your own; only a neurologist should adjust the regimen.
Last updated: 2026-08-28 · This content is for information only and is not medical advice. Consult a qualified doctor before making treatment decisions.
Back to categoriesRelated topics: Cell drug pipeline · Brain & nerves